(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 August 2025 (28.08.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/177263 A1

(51) International Patent Classification:
A61K 38/00 (2006.01) *C07K 16/22* (2006.01)
C07K 14/78 (2006.01)

(21) International Application Number:
PCT/IB2025/052005

(22) International Filing Date:
25 February 2025 (25.02.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/557,574 25 February 2024 (25.02.2024) US

(71) Applicant: **BIOHAVEN THERAPEUTICS LTD.** [US/GB]; P.O. Box 173, Kingston Chambers, Road Town, Tortola, VG1110 (VG).

(72) Inventors: **LINHARES, Brian M.**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US). **NISSANKA, Nadee**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US). **BRYSON, James**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US). **SPLIID, Charlotte**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US). **CAR, Bruce D.**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US).

(74) Agent: **ZUEV, Dmitry**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: MYOSTATIN-BINDING PROTEINS

(57) Abstract: Provided herein are polypeptides that bind myostatin with improved PK properties. Also provided are compositions comprising the same, and methods of using the polypeptides in therapeutic applications to treat neurodegenerative diseases and metabolic disorders.

WO 2025/177263 A1